Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 14/20 | 0.64 |
| ▸ | BAK1 | Q16611 | 6/20 | 0.64 |
| ▸ | BCL2L1 | Q07817 | 9/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20778266 | 0.89 | BCL2 (0.70) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL30688260 | 0.89 | BCL2 (0.70) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL1741405 | 0.85 | BCL2 (0.71) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL29846744 | 0.85 | BCL2 (0.71) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL15938164 | 0.84 | HTR7 (0.81) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL19145578 | 0.82 | HTR7 (0.81) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL19308887 | 0.81 | BCL2 (0.78) | BCL2BAK1BCL2L1 | |
| SCHEMBL22169036 | 0.81 | BCL2 (0.72) | BCL2BAK1BCL2L1HTR7ALDH1A1 | |
| SCHEMBL17350461 | 0.80 | BCL2 (0.67) | BCL2BAK1BCL2L1 | |
| SCHEMBL1743631 | 0.80 | BCL2 (0.68) | BCL2BAK1BCL2L1HTR7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | BCL2 2/4885BAK1 32/4885BCL2L1 18/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | BCL2 2/4885BAK1 32/4885BCL2L1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.